Rapidly advancing our technology platforms


We are committed to bringing impactful innovations in cell therapy

SEE OUR SCIENCE
3D image of a cell

Mission, vision, and values—the principles we live by



Close up image of scientist examining a sample

Our Mission - The pursuit of a cure

Dedicated to quality and driven by excellence, we are committed to improving the lives of patients worldwide. We are steadfast in our goal to develop innovative cellular therapies that bring us closer to a cure.

From the very beginning, we’ve been focused on science. We came together as a team of experts dedicated to quality, driven by excellence, and committed to experimentation. Though we faced many challenges, we remain fearless in our research and rigorous in our thinking, pushing ourselves to work harder.

At Legend Biotech, we have the opportunity to change the way treatments are developed across diseases and continents. Our goal is to reinvigorate treatment approaches in oncology and beyond.

The spark of hope is lit and we’re using that hope to ignite the future of cell therapy!

READ MORE [+]
Image of a cell

Our Vision - Igniting the future of cell therapy

We welcome the opportunity to reinvigorate the treatment approaches in oncology and the future of cell therapy.

Today, our research is focused on continuous innovation in the field of cell therapy. We are also future-focused on emerging technologies that can help address some of the most chronic and life-threatening diseases.

Our goal is to reimagine healthcare and to deliver transformative treatments.

And at Legend Biotech, that’s what we’re doing every day.

READ MORE [+]
Image of grandfather and granddaughter smiling

Our Values - Sharing our passion with the world

Our driving force at Legend Biotech is sharing our passion for developing cutting-edge cell therapies with our colleagues and the healthcare community. We do that by being:

Efficient: We constantly look for inspiration inside and outside the world of cell therapy.

Transparent: We work openly and collaboratively to establish trust and protect the relationships we’ve developed over time.

Passionate: We have an innate drive for scientific advancement in order to bring the power of cell therapies to patients.

Fearless: We focus on the importance of continuous learning and intellectual humility, using these attributes to advance to the next step.

Accountable: Be reliable and dependable; do what you say you will do. This idea is at the core of what we believe.

READ MORE [+]

Our leadership team brings extensive experience in developing cell therapies

Global Leadership Team

yuan xu, phd
view bio search-icon

Yuan Xu, PhD

Chief Executive Officer & Board Member
yuan xu, phd

Yuan Xu, PhD
Chief Executive Officer & Board Member, Legend Biotech

Dr Xu has been the Chief Executive Officer since February, 2018. Before joining Legend Biotech, Dr Xu was Senior Vice President at Merck where she led teams in biologics and vaccines discovery, development, and commercialization. Prior to Merck, Dr Xu held positions at Gilead, Novartis, Amgen, Chiron, GlaxoSmithKline, and Genentech.

With more than 25 years of biologic, biosimilar, vaccine and cell therapy discovery, development, commercialization, and life-cycle-management experience, Dr Xu has contributed to the successful commercial launch of nearly 25 products.

Dr Xu received her Bachelor of Science in biochemistry from Nanjing University, China, her Doctor of Philosophy in biochemistry from the University of Maryland at College Park in College Park, Maryland, USA, and completed her post-degree training in virology and gene therapy at the University of California, San Diego in San Diego, California, USA.

frank fan, md, phd
view bio search-icon

Frank Fan, MD, PhD

Co-Founder & Chief Scientific Officer
frank fan, md, phd

Frank Fan, MD, PhD
Co-Founder & Chief Scientific Officer

Dr Fan is a co-founder of Legend Biotech and its Chief Scientific Officer since 2014. Dr Fan has been published in numerous peer-reviewed academic journals, including a major revision in the clinical guidelines of pediatric organ transplantation published in Nature Medicine. Dr Fan was also awarded a “New Key Opinion Leader” award by The International Society of Transplantation.

Dr Fan earned his Doctor of Medicine degree at Xi’an Jiaotong University, China, and completed his surgical residency at the Jiaotong University Kidney Transplant Center, China. Dr Fan later obtained his Doctor of Philosophy in applied immunology at Hiroshima University, Japan, and completed postdoctoral training in the field of human B-cell tolerance at the Hospital for Sick Children at the University of Toronto, Canada.

ying huang, phd
view bio search-icon

Ying Huang, PhD

Chief Financial Officer
ying huang, phd

Ying Huang, PhD
Chief Financial Officer

Dr Huang has served as Chief Financial Officer since July, 2019. He brings over 9 years of experience in research and development at major multi-national pharmaceutical companies and 12 years of experience as a biotechnology analyst on Wall Street.

Most recently, Dr Huang was a Managing Director and Head of Biotech Equity Research at Bank of America Merrill Lynch where he led a team of analysts covering more than 30 biotechnology companies including Amgen, Gilead, Celgene, Biogen and others that encompass a wide range of therapeutic areas. His knowledge and expertise have been recognized by the Institutional Investor survey as a top ranked biotechnology analyst on Wall Street. Dr Huang has been a biotech analyst since 2007 and previously worked at Wells Fargo (formerly Wachovia), Credit Suisse, Gleacher and Barclays before joining Bank of America Merrill Lynch. Besides providing investment research to investors, Dr. Huang and his team conducted due diligence for numerous successful initial public offerings (IPOs) and follow-on offerings in the biotechnology sector.

Prior to his Wall Street career, Dr Huang was a Principal Scientist at Schering-Plough (now Merck & Co.) in the Department of Chemical Research focusing on small molecule drug discovery in the therapeutic areas of cardiovascular and central nervous system. He is the co-author of multiple patents and peer reviewed publications. Dr Huang received his Doctor of Philosophy in Bio-organic Chemistry from Columbia University, New York, USA. He also studied in the Special Class for the Gifted Young at the University of Science and Technology of China and Columbia Business School.

meeta chatterjee
view bio search-icon

Meeta Chatterjee, PhD

Senior Vice President, Global Business Development
meeta chatterjee

Meeta Chatterjee, PhD
Senior Vice President, Global Business Development

Dr Meeta Chatterjee has served as the Senior Vice President of Global Business Development since March, 2019. She was previously Head of Strategy, Transactions, and Operations within the Business Development and Licensing (BD&L) group at Merck Research Labs. Dr Chatterjee oversaw discovery and late-stage transactions worldwide, as well as early-stage transactions in key geographies. She also was responsible for Merck’s BD&L governance, oversight, and control as well as out-licensing efforts.

Dr Chatterjee has over 30 years of broad strategic and operational experience in pharmaceutical research and development, mergers and acquisition evaluation, in-licensing, and externalization activities. Over the course of her extensive career, she has led/contributed to >150 transactions/collaborations with a cumulative financial value of ~$1 billion USD. She has led research efforts in the areas of hypertension, atherosclerosis, and obesity, and was an integral contributor to the discovery of ZETIA and ZONTIVITY.

Dr Chatterjee received her undergraduate education at St. Xavier’s University in Ahmedabad, India, and Rutgers University (B.A., Hons Physics), New Jersey, USA. She received her Doctor of Philosophy in Physiology from Rutgers University and completed a postdoctoral fellowship in the Department of Physiology at the University of Virginia, School of Medicine, Virginia, USA. Dr Chatterjee is also active in industry and licensing focused organizations.

syed rizvi
view bio search-icon

Syed Rizvi, MD

Vice President, Clinical Development & Medical Affairs
syed rizvi

Syed Rizvi, MD
Vice President, Clinical Development & Medical Affairs

Dr Syed Rizvi has served as Vice President of Clinical Development and Medical Affairs since June, 2018. He also oversees data sciences and product safety functions. Dr Rizvi brings more than 20 years of successful oncology drug development experience and has been responsible for setting the medical/clinical strategy for clinical development resulting in new indications and potential label expansion. He has demonstrated a consistent track record of solid performance and clinical expertise by taking drugs successfully to health authority approvals and subsequent drug launches.

Dr Rizvi joined Legend Biotech from Celgene Corporation, where he was the head of the CAR-T program in Global Medical Affairs and also served as head of Hematology for US Medical Affairs. At Celgene, he was responsible for the strategic direction and management of the CAR-T and immuno-oncology therapy portfolios, built a comprehensive clinical research alliance, and developed an immuno-oncology network with researchers to harness scientific discovery for targeted patient outcomes. Prior to Celgene, Dr Rizvi held global clinical leadership roles in oncology programs at Novartis Oncology and Merck.

Dr Rizvi received his Doctor of Medicine degree from Dow University of Health Sciences, Pakistan, and spent several years in direct patient care.

tracy luo
view bio search-icon

Tracy Luo, MD

Vice President, Clinical Development
tracy luo

Tracy Luo, MD
Vice President, Clinical Development

Dr Tracy Luo has served as Vice President of Clinical Development, Greater China, since May, 2018. Dr Luo has a comprehensive understanding of the Chinese regulatory environment and dynamics and has more than 15 years of experience advancing clinical development programs in the oncology and hematology therapeutic areas. Previously, Dr Luo led multiple global oncology and hematology products through the clinical development stage at AstraZeneca, Amgen, and Sanofi. Her efforts led to numerous successful regulatory filings and commercial launches, including IRESSA, FASLODEX, BLINCYTO, KYPROLIS, and ELOXATIN. Previously, Dr Luo spent more than 6 years as a pharmacology research scientist at Fudan University Shanghai Medical School, China.

Dr Luo earned her Doctor of Medicine degree from Qingdao Medical College, China, and a Master of Science degree in pharmacology at Fudan University, China.

steve gavel
view bio search-icon

Steve Gavel

Vice President, Commercial Development
steve gavel

Steve Gavel
Vice President, Commercial Development

Mr Steve Gavel has served as Vice President of Commercial Development since July, 2018. He brings over 28 years of commercial experience in biotech start-ups, leading pharmaceutical and medical device organizations.

Most recently, Mr Gavel worked at Celgene Corporation, where he led US CAR-T commercial development activities for their bb2121 program. In this role, he led commercial launch strategy and execution planning in the United States. Prior to Celgene, Mr Gavel led VELCADE marketing strategy and execution at Takeda Oncology, where he served as Senior Marketing Director.

Prior to Takeda Oncology, Mr Gavel held multiple sales, marketing and market access leadership positions in companies such as Syntex, Immunex, Johnson & Johnson, and IMS Health.

Mr Gavel earned his Bachelor of Science degree in finance and business administration from Millersville University in Millersville, Pennsylvania, USA.

chong yang
view bio search-icon

Chong Yang, MD

Vice President, Commercial Development
chong yang

Chong Yang, MD
Vice President, Commercial Development

Dr Chong Yang has served as Vice President of Commercial Development, Greater China since July, 2018. Formerly, Dr Yang held various sales and marketing leadership roles with increasing responsibilities in multinational pharmaceutical companies including Roche Oncology, Bayer Oncology, and Novartis Oncology. He brings more than 17 years of commercial experience and has extensive expertise in promoting and launching products including GLIVEC, NEXAVAR, AVASTIN, and RITUXAN in the China market.

Dr Yang earned his Master of Medicine degree from Nanjing University, China, and served as a Surgical Resident at Zhongda Hospital at Southeast University, China.

liz gosen
view bio search-icon

Liz Gosen

Senior Vice President, Technical Operations
liz gosen

Liz Gosen
Senior Vice President, Technical Operations

Ms Liz Gosen has served as Senior Vice President of Technical Operations since May, 2019. Prior to joining Legend Biotech, she was Vice President of Biologics Operations at Eli Lilly where she was responsible for the manufacturing, warehouse, and supply chain organizations for a 2-suite multi-product commercial and clinical monoclonal antibody (mAb) manufacturing facility.

During her 25-year career she has developed a broad experience in biotechnology manufacturing operations through assignments in the following areas: multiple large-scale manufacturing facility capital design/builds and start-ups, process engineering support and management, facility and utilities management, site process technology transfers, and successful process validation as well as operations, logistics, and validation management.

Ms Gosen has international commercial scale manufacturing experience as a Business Unit Leader of an Eli Lilly large-scale mAb facility in Ireland. She was responsible for the organizational build and development of the operations organization from the commissioning and qualification support phase through to FDA approval and commercial operations. Ms Gosen has extensive global regulatory inspection experience and has been directly involved in the worldwide regulatory submission, pre-approval inspection, and launch of five biologics products.

Ms Gosen holds a Bachelor of Science Degree in Materials Science & Engineering with a minor in Biology from Lehigh University, Pennsylvania, USA, and an MBA of Finance from Seton Hall University, New Jersey, USA.

david he
view bio search-icon

Donggou (David) He, MD, PhD

Vice President, Technical Operations
david he

Donggou (David) He, MD, PhD
Vice President, Technical Operations

Dr David He has served as Vice President of Technical Operations (previously Vice President of Manufacturing) since May, 2018. Previously, he was the Head of Clinical Science & Technology at Boehringer Ingelheim, leading the Good Manufacturing Practice (GMP) Clinical Manufacturing and Manufacturing Science and Technology/Tech transfer teams. Dr He has held research and manufacturing positions of increasing responsibilities in large US pharmaceutical companies and has more than 25 years of experience working in both industry and academic settings with expertise in the fields of biologics development, chemistry, manufacturing and control (CMC) process development, and cGMP manufacturing. Dr He has developed a number of successful manufacturing processes for biologics, which have led to cFDA/FDA/EMA approval. He has extensive cross-functional leadership and hands-on experience in CMC process development and manufacturing (from lab scale through pilot scale to large-scale cGMP manufacturing), as well as a depth of experience in tumor cell biology, tumor immune cell therapy, and molecular biology.

Dr He completed his postdoctoral training in immunology from the University of Alabama at Birmingham in Birmingham, Alabama, USA. He received his Doctor of Philosophy degree in molecular biology from Sun Yat-sen University, China; a Master of Science degree in oncology (tumor cell biology and immunology) from Guangzhou Medical University, China; and a Doctor of Medicine degree from Hengyang Medical College, China.

alan kick
view bio search-icon

Alan Kick

Vice President, Global Quality
alan kick

Alan Kick
Vice President, Global Quality

Mr Alan Kick has served as Vice President of Global Quality since August, 2018. Prior to joining Legend Biotech, Mr Kick was Executive Director of Quality Operations at Celgene Corporation, responsible for the Global External Quality, Cell Therapy Quality, and Global Quality Supply Chain organizations. He previously held positions of increasing responsibility at Dendreon, Wyeth, Johnson & Johnson, and Hoffmann-La Roche. Mr Kick has nearly 30 years of experience in the pharmaceutical industry, including solid oral dosage, semi-solids, biologics, vaccines, sterile lyophilized products, cellular therapies, active pharmaceutical ingredient (API), commercialization, development, and laboratory management.

Mr Kick received a Bachelor of Science degree in biology from The College of New Jersey in Ewing, New Jersey, USA, and a Master of Science degree in business management from New Jersey Institute of Technology in Newark, New Jersey, USA.

yuhong qiu
view bio search-icon

Yuhong Qiu, PhD

Vice President, Global Regulatory Affairs
yuhong qiu

Yuhong Qiu, PhD
Vice President, Global Regulatory Affairs

Dr Yuhong Qiu has served as Vice President of Global Regulatory Affairs since May, 2018. Previously, Dr Qiu served as Executive Director of Regulatory Affairs at Novartis Oncology, where she worked for 12 years with increasing responsibilities. She has broad regulatory expertise spanning across both small and large molecule (biologics) development. Dr Qiu has led numerous successful global regulatory filings from first-to-human studies to marketing authorization applications. Before joining Novartis Oncology, Dr Qiu worked for 8 years at Johnson & Johnson, where she led a team of scientists in drug discovery and gained rich experience in drug candidate selection and characterization and preparation of nonclinical documents for first-in-human studies.

Dr Qiu received her Doctor of Philosophy degree and completed her postdoctoral training from the Baylor College of Medicine in Houston, Texas, USA. She received her Bachelor of Science degree in biochemistry from Wuhan University, China. Dr Qiu has authored or co-authored more than 30 publications in peer-reviewed journals.

simon wu
view bio search-icon

Shu (Simon) Wu

Vice President, Operations
simon wu

Shu (Simon) Wu
Vice President, Operations — Research & Development Institute II

Mr Shu (Simon) Wu has served as Vice President of Operations, Research & Development Institute II, since October, 2017. Formerly, Mr Wu was the Vice President of Operations for the Discovery Biology Business Unit at GenScript Inc., leading antibody therapeutics discovery and operations activities. Mr Wu is the co-inventor of 15 patents in the field of immunotherapy and has more than 10 years of therapeutic antibody discovery and development, organizational capability building, and management experience. He has contributed to the development of successful novel discovery platforms and has led many antibody and chimeric antigen receptor T-cell (CAR-T) candidates into clinical development.

Mr Wu received his Master of Science degree in molecular biology from the Chinese Academy of Science, China, and a Bachelor of Arts degree in microbiology from Nanjing Agriculture University, China.



Board of Directors

frank zhang, phd
view bio search-icon

Frank Zhang, PhD

Board Chairman, Legend Biotech
Chief Executive Officer, GenScript Inc.
frank zhang, phd

Frank Zhang, PhD
Board Chairman, Legend Biotech
Chief Executive Officer, GenScript Inc.

For the past 16 years, Dr Zhang has been the Chairman and Chief Executive Officer of GenScript Inc., the world’s largest gene synthesis corporation. In 2014, Dr Zhang founded Legend Biotech under GenScript Inc., expanding the corporation’s business goal to research, manufacture, and commercialize a broad range of immunotherapy treatments. In 2018, Legend Biotech became the first Chinese CAR-T company to receive Investigational New Drug approval in both China and the United States. That same year, Dr Zhang was awarded Person of the Year at the China Healthcare Summit in recognition of his contribution to and significant impact on the healthcare field.

Before founding GenScript Inc., Dr Zhang worked as a Principal Scientist at Schering-Plough from 1995 to 2002 where he received its Presidential Award. Dr Zhang received his PhD in biochemistry from Duke University in Durham, North Carolina, USA; and his Master’s degree from Nanjing University, China. Dr Zhang has authored more than 20 articles published in peer-reviewed journals and is owner of 9 scientific patents.

yuan xu, phd
view bio search-icon

Yuan Xu, PhD

Board Member, Chief Executive Officer, Legend Biotech
yuan xu, phd

Yuan Xu, PhD
Board Member, Chief Executive Officer, Legend Biotech

Dr Xu has been the Chief Executive Officer since February, 2018. Before joining Legend Biotech, Dr Xu was Senior Vice President at Merck where she led teams in biologics and vaccines discovery, development, and commercialization. Prior to Merck, Dr Xu held positions at Gilead, Novartis, Amgen, Chiron, GlaxoSmithKline, and Genentech.

With more than 25 years of biologic, biosimilar, vaccine and cell therapy discovery, development, commercialization, and life-cycle-management experience, Dr Xu has contributed to the successful commercial launch of nearly 25 products.

Dr Xu received her Bachelor of Science in biochemistry from Nanjing University, China; her Doctor of Philosophy in biochemistry from the University of Maryland at College Park in College Park, Maryland, USA; and completed her post-degree training in virology and gene therapy at the University of California, San Diego in San Diego, California, USA.

sally wang, ms
view bio search-icon

Sally Wang, MS

Board Member, Legend Biotech
President, GenScript Inc.
sally wang, ms

Sally Wang, MS
Board Member, Legend Biotech
President, GenScript Inc.

Ms Wang is the President of GenScript Inc. and a board member for Legend Biotech Corporation, responsible for the companies’ strategies and overall operational management. Prior to joining the organization, she worked as an Environmental Monitoring Engineer at Shenzhen Futian Environment Protection Surveillance Station for nearly a decade.

Ms Wang holds several advanced degrees, including a Master of Science degree from Wuhan University, China, in August 1993; a Master’s degree in Computer Sciences from Bridgeport University in Bridgeport, Connecticut, USA; and an Executive Master of Business Administration degree from the China Europe International Business School, China.


The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

*LCAR-B38M identifies the investigational product being studied in China and Janssen Biotech, Inc.'s JNJ-68284528 (also referenced as JNJ-4528) identifies the investigational product being studied in the United States, both of which are representative of the same CAR-T cell therapy.

X

But we are just getting started!

You are about to leave LegendBiotech.com.
Are you sure you want to leave so soon?

I AM SURE
KEEP ME HERE

By continuing to use our site, you agree to terms on our Legal Notice.
You can learn more about how we use cookies by viewing our Legal Notice.

CLOSE